Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD

Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD).